How Ozempic Changed American Culture

In 2018, “Ozempic” was a drug name most Americans had never heard, attached to a TV ad set to a 1974 pop song. By 2026 it was a punchline, an accusation, a compliment, a political talking point, a food industry label and a category of plastic surgery.

That is an unusual amount of cultural work for a prescription medication. Here is what actually changed, with the evidence behind each shift.

Why does everyone say “Ozempic” when they mean something else?

Start here, because the imprecision matters.

• Ozempic is semaglutide, approved for type 2 diabetes.
• Wegovy is semaglutide, approved for weight management.
• Mounjaro and Zepbound are tirzepatide, a different molecule from a different company.
• Rybelsus is oral semaglutide for type 2 diabetes.

Ozempic got there first culturally, so its name became the generic label - the way “Band-Aid” absorbed every adhesive bandage. It also spawned a family of coinages: Ozempic face, Ozempic babies, Ozempic Santa, Ozempidemic [1].

The confusion is not harmless. Coverage rules, labeled indications and side effect profiles differ by drug and by indication. Somebody saying “my insurance won’t cover Ozempic for weight loss” is describing a real situation - Ozempic’s label does not carry a weight-management indication - that gets muddled when the word is used to mean the whole class.

By 2026, prescription records showed tirzepatide had actually become the most-prescribed GLP-1 agent in the US, well ahead of semaglutide. The most common word for these drugs no longer points at the most common drug.

When did this become a thing everyone knew about?

There is a fairly precise answer: March 12, 2023.

Two minutes into hosting the 95th Academy Awards, Jimmy Kimmel looked out at the room and said: “Everybody looks so great. When I look around this room, I can’t help but wonder, is Ozempic right for me?” [2]

The joke worked because the audience already got it. Hollywood had been whispering about the drug for months. Kimmel made the whisper public, and the coverage that followed treated Ozempic as a known quantity rather than something requiring explanation.

The setup had come six months earlier. In October 2022, Elon Musk answered a follower asking about his fitness with one word - “Fasting” - and then a follow-up: “And Wegovy” [3]. It was the first disclosure from a public figure with a truly mass audience.

Then the disclosures stacked up. Chelsea Handler said in January 2023 that her anti-aging doctor “just hands it out to anybody” and that she had not realized she was on Ozempic [4]. Amy Schumer said in June 2023 that she had tried it, felt too sick to function, and that other celebrities were “lying” about smaller portions [4]. Tracy Morgan told TODAY in August 2023, “That’s Ozempic. That’s how this weight got lost” [4].

What made it respectable instead of just gossip?

One hour of television.

In December 2023, Oprah Winfrey told People she uses a prescription weight-loss medication - she has never named the brand - describing it as “a tool to manage not yo-yoing” and saying she had wrongly blamed herself for years [4]. In February 2024 she left the WeightWatchers board and donated her shares, saying she did not want the appearance of a conflict of interest [5].

On March 18, 2024, ABC aired An Oprah Special: Shame, Blame and the Weight Loss Revolution, an hour with obesity medicine physicians and patients in front of a live studio audience [6]. The framing was medical: obesity as a disease, willpower as an inadequate explanation, medication as treatment.

The very next day, Whoopi Goldberg told her co-hosts on The View that she had used Mounjaro after reaching close to 300 pounds during the filming of Till. Co-host Sunny Hostin said she had used it too [4]. Two months later Kelly Clarkson confirmed on her own show that she takes a prescription, adding: “Everybody thinks it’s Ozempic. It’s not” [4].

Within about ninety days, the story moved from tabloid speculation to daytime television confession. That is the hinge.

How did these drugs change the way Americans talk?

Three phrases entered ordinary speech, and each one carries an argument inside it.

“Food noise.” This describes persistent, intrusive thoughts about food. The phrase came from patients, not from a lab. A 2025 consensus paper in Nutrition & Diabetes proposed a formal definition - persistent thoughts about food that the person experiences as unwanted or distressing - after the term was already in mass circulation [7]. Google searches for it first appeared in November 2006, rose sharply in fall 2022 and peaked in spring 2024 [7].

The reason it spread is that it gave millions of people a name for something they had experienced their whole lives without vocabulary for. Rosie O’Donnell put it plainly: “I was stunned how it quieted the food noise” [8]. Once you can name it, “just eat less” starts to sound like advice about the wrong problem.

“Ozempic face.” Facial volume loss and sagging after rapid weight loss. The term is not clinically specific - substantial fast weight loss from any cause can do it - but it became a marketing category. In the American Academy of Facial Plastic and Reconstructive Surgery’s December 2025 annual survey, reported by Medscape, 67% of responding surgeons said they were seeing more patients seeking treatment for aesthetic changes tied to rapid weight loss, a 45% increase over 2024 [9]. The American Society of Plastic Surgeons now publishes patient guidance on procedures used to address it [10].

“Ozempic babies.” The label for unplanned pregnancies among people taking GLP-1s. Two mechanisms are usually cited: weight loss restoring regular ovulation, and delayed stomach emptying potentially reducing absorption of oral contraceptives [11]. The Mounjaro and Zepbound labels warn specifically about oral contraceptive effectiveness. Clinicians commonly advise stopping at least two months before trying to conceive, per prescribing information [11]. If you are on a GLP-1 and using oral birth control, that is a conversation to have with a healthcare provider rather than a social media thread.

Did the drugs actually change how the country looks?

Gallup’s tracking says the US adult obesity rate fell from a record 39.9% in 2022 to 36.8% in 2026, a decline Gallup describes as statistically meaningful and as inversely tracking rising GLP-1 use [12]. Gallup’s obesity figures rely on self-reported height and weight, and a few years of correlation is not proof of cause - but it is the first sustained decline in that trend line in decades.

Meanwhile 90% of Americans now know about GLP-1 drugs for weight loss, up from 80% in 2024 [12]. And KFF found that 37% of US adults have a close friend or family member using one [13].

That last number explains the feeling that this is everywhere. Only about one in eight adults is actually taking one. But more than a third of the country is one relationship away from someone who is.

Why did the advertising get so loud?

Because the business model changed.

In February 2025, Hims & Hers became the first company to advertise GLP-1 weight-loss offerings during a Super Bowl. Two senators - Dick Durbin and Roger Marshall - wrote to the FDA before the spot aired, saying it “risks misleading patients” by omitting safety information, and noting that the “not FDA-approved” disclaimer for its compounded product flashed for about three seconds in small type [14]. The company said it was complying with existing law. Traffic to its site spiked 650% [14].

By Super Bowl LX on February 8, 2026, four companies ran weight-loss advertising around the same game: Novo Nordisk with an in-game Wegovy pill spot featuring Kenan Thompson, DJ Khaled, Danielle Brooks, Ana Gasteyer, John C. Reilly and Danny Trejo; Ro with Serena Williams; Hims & Hers with a Common voiceover and the line “Rich people live longer”; and Eli Lilly, which hedged with a 60-second Zepbound spot, “Watch This,” in the pre-game window rather than in the game itself [15]. Thirty seconds of in-game airtime passed $10 million for the first time.

Three days before kickoff, the FDA had told Novo Nordisk that its first Wegovy pill TV ad - which debuted during the Golden Globes on January 11, 2026 - was false or misleading, saying phrases like “live lighter” and “a way forward” implied benefits beyond weight loss and positioned the drug as “a solution to broader life challenges” [16].

Comedy kept pace with commerce. In March 2024, Saturday Night Live ran “Ozempic for Ramadan,” a parody commercial with Ramy Youssef pitching a pork-free semaglutide injection for people fasting during the holy month [17]. Two years later an SNL pharma-ad parody reached for the Ozempic jingle and had a voiceover concede it was already taken.

That jingle, incidentally, is “Magic,” a 1974 hit by the Scottish band Pilot, licensed by Novo Nordisk in 2018 with the hook changed from “Oh, oh, oh, it’s magic” to “Oh, oh, oh, Ozempic” [18]. Nobody involved has disclosed the money. The New York Times reported that music-publishing executives it polled estimated the campaign was “most likely worth seven figures” to songwriter David Paton, who co-wrote the song and later re-recorded it at Abbey Road for the ad [18].

Did the argument about willpower actually get settled?

No. It flipped venues.

For decades the cultural argument about weight was about effort. GLP-1s reframed it: if a medication reliably changes appetite, then appetite was never purely a matter of discipline. Oprah’s framing - “I have a predisposition that no amount of willpower is going to control” - was the mass-market version of that shift [4].

But a new judgment replaced the old one, and researchers have measured it. A Georgetown study published April 9, 2026 in the American Psychological Association journal Stigma & Health put 402 US women through the test, and found they expressed more fat phobia, more dislike, more blame and more desire for social distance toward a woman who lost 15% of her body weight with a GLP-1 than toward one who lost the same weight through diet and exercise [19]. “Shortcut” beliefs were the main driver, and - to the researchers’ surprise - the judgment was harsher when the woman in the vignette was depicted as white rather than Black. A separate study found that a lean woman who lost weight with a GLP-1 drew the same level of negative evaluation as a woman with obesity who used the same method.

An August 2026 commentary in the International Journal of Obesity gave this a name: treatment-related stigma, a form of judgment that extends past body size to the perceived moral legitimacy of pharmacologic treatment.

This is the practical reason so many people do not tell anyone. It also explains why Serena Williams made a point of saying, “A misconception is that a GLP-1 is a shortcut… believe me, I don’t take shortcuts” [4].

What happened to body positivity?

The fashion numbers are stark.

Vogue Business, analyzing every runway show on the official New York, London, Milan and Paris schedules for spring/summer 2025, found 0.8% of 8,763 looks were plus-size (US 14+) and 94.9% were US size 0 to 4. It warned of “a worrying return to using extremely thin models, amid the Ozempic boom” [20]. Its fall/winter 2026 report, covering 7,817 looks across 182 shows, put plus-size representation at 0.3% - the lowest since Vogue Business started counting - and named “growing use of GLP-1s” as part of the backdrop [21].

British Vogue’s editorial director Chioma Nnadi told BBC Radio 4 the industry “should be concerned,” adding, “I do think maybe perhaps Ozempic has something to do with it” [22].

Lizzo, who spent a decade as the most visible advocate for plus-size visibility and who has herself used a GLP-1, wrote in November 2025 that extended sizes are vanishing and plus-size models are “no longer getting booked,” concluding: “We have a lot of work to do, to undo the effects of the ozempic boom” [23].

The counter-argument, made by clinicians and by many users, is that treating a medical condition and respecting people in larger bodies are not opposites, and that the cultural drift toward thinness was well underway before these drugs existed. Both things can be true.

What changed in ordinary life?

Smaller shifts that add up:

• Dating. A Kinsey Institute survey found 50% to 60% of GLP-1 users reported at least one change in their dating or sex life, with effects running in both directions. Men were about three times more likely than women to report more confidence in their appearance and more dating-app matches [24].
• Shopping. PwC found GLP-1 households spending 5.5% less on groceries and 9.9% more on apparel after six to eight months, with 73% reporting a meaningful change in clothing size [25].
• Peer support. Reddit communities became the main infrastructure of the era. A 2026 University of Pennsylvania study analyzed more than 400,000 GLP-1-related posts and argued these forums function as an early-warning system for side effects that do not surface in clinical trials or short office visits [26]. PwC found only 9% of current users have a GLP-1-specific app and nearly a quarter say they are figuring it out on their own [25].

Why is this a political story now?

Because the drugs are expensive and effective at the same time, which forces a decision.

In September 2024, Sen. Bernie Sanders brought Novo Nordisk’s CEO before the Senate HELP Committee and argued Americans pay nine times the German net price for Ozempic. In November 2025, President Trump announced pricing deals with Eli Lilly and Novo Nordisk at an Oval Office event where he repeatedly called the medicines “the fat drug” [27]. And on July 1, 2026, Medicare began a demonstration - the Medicare GLP-1 Bridge - letting eligible Part D beneficiaries pay a flat $50 copay for certain GLP-1 drugs prescribed for chronic weight management. CMS has it running through December 31, 2027. It is the first time the program has paid toward weight-loss-only use at scale.

Health and Human Services Secretary Robert F. Kennedy Jr. traveled the full arc in public: from arguing that good food three times a day could solve obesity overnight, to conceding the drugs “have a place,” to backing expanded access as a tool against chronic disease.

What has not changed?

Two things, and they are the ones most worth remembering.

These are chronic medications, not a course of treatment. Northwestern Medicine clinicians estimate that 50% to 75% of people who start these drugs stop within a year - an estimate, widely repeated in clinical and trade reporting, rather than a single trial result. Oprah Winfrey told People in December 2025 that she quit for about a year, regained roughly 20 pounds despite keeping up diet and exercise, restarted, and concluded: “It’s going to be a lifetime thing” [28]. Charles Barkley and Harvey Fierstein have described similar regain after stopping.

Access is still unequal. KFF found 56% of users said the drugs were difficult to afford, including 25% who said “very difficult,” and 27% had insurance but paid the full cost themselves [13]. The cultural moment arrived faster than the coverage did.

Nothing here is medical advice, and nothing here can tell you whether one of these drugs makes sense for you - that is a conversation for a healthcare provider who knows your history. But the cultural shift is real, it is documented, and it happened faster than almost any comparable change in American health behavior.

Sources

1. Wiktionary, “Ozempidemic” — https://en.wiktionary.org/wiki/Ozempidemic
2. The Independent, “Jimmy Kimmel makes Ozempic weight loss joke during Oscars monologue” (March 13, 2023) — https://www.the-independent.com/life-style/ozempic-jimmy-kimmel-oscars-monologue-last-night-b2299732.html
3. Elon Musk on X, “And Wegovy” (October 1, 2022) — https://x.com/elonmusk/status/1576367983051489281?lang=en
4. TODAY, “32 Celebrities Who’ve Opened Up About Taking Ozempic or Weight-Loss Drugs” — https://www.today.com/health/celebrities-on-ozempic-rcna129740
5. Variety, “Oprah Winfrey Reveals Why She Quit WeightWatchers Board of Directors” (March 16, 2024) — https://variety.com/2024/tv/news/why-oprah-winfrey-quit-weightwatchers-board-1235942994/
6. ABC, “Watch ‘An Oprah Special: Shame, Blame and the Weight Loss Revolution’” (March 18, 2024) — https://abc.com/news/13e11c19-1f4d-4bea-8765-52d0fdbe8160/category/1138628
7. Nutrition & Diabetes, “Food noise: definition, measurement, and future research directions” (September 3, 2025) — https://www.nature.com/articles/s41387-025-00382-x
8. Everyday Health, “17 Celebrities Who’ve Taken GLP-1 Weight Loss Drugs” (August 11, 2026) — https://www.everydayhealth.com/weight/13-celebrities-who-have-spoken-out-about-taking-glp-1s
9. Medscape, “GLP-1 Drugs: Is Ozempic Face Changing Aesthetic Care?” (July 22, 2026) — https://www.medscape.com/viewarticle/glp-1-drugs-ozempic-face-changing-aesthetic-care-2026a1000osv
10. American Society of Plastic Surgeons, “How plastic surgery can address ‘Ozempic face’” (June 24, 2025) — https://www.plasticsurgery.org/news/articles/how-plastic-surgery-can-address-ozempic-face
11. WFYI / Side Effects Public Media, “The Checkup: Ozempic babies?” (April 26, 2024) — https://www.wfyi.org/news/articles/the-checkup-ozempic-babies-explaining-unexpected-pregnancies-on-glp-1-drugs
12. Gallup, “In U.S., GLP-1 Usage Reaches New High” (July 7, 2026; updated September 8, 2026) — https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx
13. KFF, “KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use” (November 14, 2025) — https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/
14. Fierce Healthcare, “Hims & Hers sees 650% spike in traffic following Super Bowl ad” (February 13, 2025) — https://www.fiercehealthcare.com/health-tech/hims-hers-sees-650-spike-traffic-following-super-bowl-ad-clash-over-compounded-glp-1s
15. Adweek, “GLP-1 Brands Enter Their Super Bowl Era” (February 9, 2026) — https://www.adweek.com/brand-marketing/glp-1-brands-enter-their-super-bowl-era/
16. U.S. Food and Drug Administration, Wegovy Untitled Letter (February 5, 2026) — https://www.fda.gov/media/191020/download
17. Deadline, “Ramy Youssef Gets ‘Ozempic For Ramadan’ In ‘SNL’ Sketch” (March 31, 2024) — https://deadline.com/2024/03/snl-ramy-youssef-ozempic-for-ramadan-1235872512
18. The New York Times, “How Ozempic Turned a 1970s Hit Into an Inescapable Jingle” (April 9, 2024) — https://www.nytimes.com/2024/04/09/arts/music/ozempic-jingle-oh-oh-oh-its-magic-pilot.html
19. Georgetown Lombardi Comprehensive Cancer Center, “New study examines stigma toward women who lose weight using GLP-1 medications” (April 10, 2026) — https://lombardi.georgetown.edu/news-release/new-study-examines-stigma-toward-women-who-lose-weight-using-glp-1-medications
20. NBC News, “Is the era of body positivity over?” — https://www.nbcnews.com/pop-culture/viral/era-body-positivity-experts-worry-return-thinness-norm-rcna184050
21. Vogue Business, “The Vogue Business Fall/Winter 2026 size inclusivity report” — https://www.vogue.com/article/the-vogue-business-fall-winter-2026-size-inclusivity-report
22. ELLE Canada, “Skinny Culture Is Back With a Vengeance” (July 20, 2026) — https://www.ellecanada.com/beauty/health-and-fitness/skinny-culture-is-back-with-a-vengeance-so-whatever-happened-to-body-positivity
23. Northwestern Now, “Why do 50-75% of people stop taking GLP-1 drugs within a year?” (November 8, 2024) — https://news.northwestern.edu/stories/2024/11/why-do-50-75-of-people-stop-taking-glp-1-drugs-within-a-year
24. BBC News, “Body positivity: Skinnier models picked for Paris Fashion Week” — https://www.bbc.com/news/articles/c62elpm2md2o
25. TODAY, “Lizzo Responds to Weight Loss Backlash” (November 24, 2025) — https://www.today.com/health/mind-body/lizzo-essay-backlash-weight-loss-body-positive-rcna245605
26. Indiana University / Kinsey Institute, “Survey shows GLP-1 weight-loss drugs are changing sex and dating for 50-60% of users” (July 16, 2025) — https://news.iu.edu/kinseyinstitute/live/news/46263-survey-shows-glp-1-weight-loss-drugs-are-changing
27. PwC, “GLP-1 consumer trends 2026” (June 22, 2026) — https://www.pwc.com/us/en/industries/consumer-markets/library/glp-1-consumer-trends.html
28. ScienceDaily / University of Pennsylvania, “AI scans 400,000 Reddit posts and finds hidden Ozempic side effects” (May 23, 2026) — https://www.sciencedaily.com/releases/2026/05/260523103914.htm
29. CBS News, “Trump announces deal to lower weight loss drug prices in some cases” (November 6, 2025) — https://www.cbsnews.com/news/trump-deal-lower-weight-loss-drug-prices-some-cases
30. People, “Oprah Reveals She Stopped Using GLP-1s for 12 Months” (December 31, 2025) — https://people.com/oprah-reveals-she-stopped-using-glp1s-for-12-months-and-shares-exactly-what-happened-exclusive-11877163